Anti-CTLA4 / Anti-PD-1 bispecific antibody and use thereof

MYPI2025007378A0Undetermined Publication Date: 2021-02-02AKESO BIOPHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025007378
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-12-02
Filing Date
2020-07-31
Publication Date
2021-02-02
Patent Text Reader

Abstract

The present invention relates to the field of tumor treatment and molecular immunology, and particularly, to an anti-CTLA4 / anti-PD-1 bispecific antibody and use thereof. Specifically, the anti-CTLA4 / anti-PD-1 bifunctional antibody comprises a first protein functional region targeting PD-1 and a second protein functional region targeting CTLA4, wherein, according to the EU numbering system, the heavy chain constant region of the immunoglobulin comprised in the bispecific antibody has mutations at any 2 or 3 of positions 234, 235 and 237, and the affinity constant of the bispecific antibody to FcγRIIIa and / or C1q is reduced after the mutation as compared to that before the mutation. The bifunctional antibody of the present invention can well and specifically bind to CTLA4 and PD-1, specifically relieve immunosuppression of CTLA4 and PD-1 in an organism, and activate T lymphocytes, thus having good application prospect.
Need to check novelty before this filing date? Find Prior Art